NICE to review wider use of off-label prescribing
October 5, 2011Sales and Marketing off label, off label prescribing
The government has asked NICE to review its plans to give doctors greater freedom for ‘off-label’ prescribing. It wants NICE, …
Blocking pain – a long-term mission for pharma research
October 5, 2011Research and Development chronic pain, neuropathic pain, pain therapeutics
Pain is a common, yet complex, clinical problem and one which remains an area of unmet need. There are however, …
Steve Mott joins DrugLogic
October 5, 2011Research and Development appointment, outcomes research, personalised medicine, pharmacovigilance, research and development
Former Datapharm Communications chief executive Steve Mott has been apppointed UK managing director by DrugLogic.The US firm develops analytical tools …
Contract research news in brief
October 5, 2011Research and Development research and development news
Clinipace raises $15m, PPD appoints a new chief executive and there are updates from Quintiles, PharmaNet and DaVita Clinical Research. …
Health reforms will do ‘irreparable’ damage to public health
October 4, 2011NHS reforms
Doctors have urged the House of Lords to reject the Health and Social Care Bill, saying the proposed legislation will …
Adaptimmune makes board appointments
October 4, 2011Manufacturing and Production, Research and Development appointment, manufacturing and production, research and development
UK and US-based cell therapy company Adaptimmune has made two new appointments to its board. Dr Jonathan Knowles joins as …
Manufacturing makes a comeback at Roche’s Nutley site
October 4, 2011Manufacturing and Production Roche, pharma manufacturing news
Roche has opened a new manufacturing facility at its campus in Nutley, New Jersey, that will supply dosage forms for …
Merck pays $1.5m penalty for US pollution
October 4, 2011Manufacturing and Production Merck & Co, pharma manufacturing news
Merck & Co has fallen foul of US regulations on environmental controls at two manufacturing plants and agreed to pay …
Digital Pharma: NHS-backed health social network launches
October 3, 2011Medical Communications Digital Pharma blog, NHS, social media
A new NHS-backed social network has launched to provide support to patients with long-term conditions through ‘personal health planning’. How …
Pharma manufacturing news in brief
October 3, 2011Manufacturing and Production pharma manufacturing news
Our round-up of pharma manufacturing news sees a green energy drive from GSK, facility updates from Stirling Pharma, Reckitt Benckiser …
Takeda completes Nycomed acquisition, installs new chief executive
October 3, 2011Sales and Marketing Nycomed, Takeda
Takeda Pharmaceutical Company has completed its acquisition of Nycomed and named Frank Morich as chief executive of the Zurich-based firm. …
Trial disappointment for AZ lung cancer drug
October 3, 2011Research and Development, Sales and Marketing AstraZeneca, selumetinib
AstraZeneca’s lung cancer drug selumetinib has failed to hit its primary endpoint in a Phase II trial. The trial compared …
SHL receives Good Design Award for Molly Auto Injector
October 3, 2011Manufacturing and Production auto injector, autoinjector, good design award, molly
SHL Group is honored to have recently received certification for the Good Design Award for its revolutionary auto injector, Molly. …
Jean-Pierre Garnier elected chairman of Actelion
October 3, 2011Sales and Marketing appointment, sales and marketing
Jean-Pierre Garnier has been elected chairman of Swiss biopharmaceutical company Actelion. He has sat on the company’s board since May …
Chinese API supplier under FDA scrutiny
October 3, 2011Manufacturing and Production Sichuan Pharmaceutical, pharma manufacturing news
Chinese active ingredient manufacturer Sichuan Pharmaceutical has been sent a warning by the US FDA for failing to sort out …
Janssen repeats digital award success
September 30, 2011Medical Communications PM Society Digital Awards
Janssen was once again the standout winner at last night’s PM Society’s Digital Media Awards. The pharma company beat its …
NICE says no to lupus treatment
September 30, 2011Sales and Marketing Benylsta, GSK, Lupus, NICE
NICE has rejected GSK’s new lupus treatment Benlysta in draft guidance.Co-developed with biotech company HGS, the drug has been hailed …
Chiltern expands North American Operation with a new office in Illinois
September 30, 2011Research and Development
Mr. Barry Simms, Chiltern’s Country Manager, North America, commented, “Chiltern continues to look for opportunities to increase our strategic footprint …
Astellas abandons oral anticoagulant darexaban
September 30, 2011Research and Development Astellas, Eliquis, Xarelto, darexaban
Astellas Pharma has abandoned the development of its oral direct factor Xa inhibitor darexaban. The Japanese firm blamed both the …
NICE refuses to back Sanofi’s Jevtana
September 30, 2011Sales and Marketing Jevtana, NICE
NICE has not recommended Sanofi’s prostate cancer drug Jevtana due to its high cost and concerns over its safety data. …
Latest content
Major funding opportunity opens for early cancer diagnostics
Androlabs receives UK authorisation for new Testavan presentation
CEPI backs African-led Bundibugyo Ebola vaccine development
Cytomos appoints life sciences executive to board
